| 06.29.22 | Scilex sues Apotex to block generic pain patch; J&J's all-oral, once-daily cancer regimen advances

Click here to subscribe to Fiercebiotech.com

2 years ago

Html
Text

Fact Sheet: OptiDose®️ Design Solution

Discover Catalent’s new OptiDose®️ Design Solution, a comprehensive drug design assessment consisting of a holistic review of the molecule, patient, and market consideration. Learn more.

Today's Rundown

With SPAC merger looming, Scilex sues Apotex to block generic copy of key pain patch Planning all-oral, once-daily regimen, J&J gets EMA backing for Imbruvica-venetoclax combination DermBiont's topical gel hits goal in benign skin growth phase 2, clearing path for further development Amid monkeypox outbreak, Siga Technologies nabs $13M in smallpox drug orders The 15 highest paid biopharma CEOs of 2021 'The Top Line' podcast: Why we need an Alzheimer's moonshot, a controversial take on diversity in biotech, plus this week's headlines

Featured Story

With SPAC merger looming, Scilex sues Apotex to block generic copy of key pain patch

By Nick Paul Taylor

Scilex has moved to neutralize a threat to a product that is central to its upcoming SPAC merger, starting a legal case against Apotex to protect its lidocaine patch from a potential competitor.

Webinar: Unraveling the Complexities in Nasal Vaccine Development, Manufacturing and Device Selection

Wednesday, June 29 | 11am ET / 4pm GMT / 5pm CET

In this webinar, experts will share insights into developing intranasal vaccine analytical tools and how to improve the speed and quality of critical batch release and characterization assays. Register Now.

Planning all-oral, once-daily regimen, J&J gets EMA backing for Imbruvica-venetoclax combination

By Nick Paul Taylor

Johnson & Johnson is a step closer to realizing its vision of creating an all-oral, once daily, fixed-duration treatment regimen for chronic lymphocytic leukemia (CLL) patients. The Big Pharma’s strategy advanced last week when the European Medicines Agency’s (EMA) drug review committee backed the candidate.

DermBiont's topical gel hits goal in benign skin growth phase 2, clearing path for further development

By Nick Paul Taylor

DermBiont’s bet on SeylanMED has delivered a win in phase 2. Twenty months after acquiring the topical drug candidate SM-020, DermBiont has linked the prospect to improved outcomes in people with benign tumors, causing the phase 2 clinical trial to meet its primary and secondary endpoints.

Amid monkeypox outbreak, Siga Technologies nabs $13M in smallpox drug orders

By Zoey Becker

Siga Technologies' oral smallpox antiviral, Tpoxx, is racking up orders as the monkeypox outbreak spreads.

The 15 highest paid biopharma CEOs of 2021

By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Kevin Dunleavy,Zoey Becker

In a year in which biopharma revenues increased dramatically, especially among companies that brought COVID-19 products to the market, many firms laid out eye-popping pay packages for their chief executives. Bookending this year's list are longtime CEOs who retired from powerhouse U.S. companies during the year—No. 1 Alex Gorsky of Johnson & Johnson and No. 15 Ken Frazier of Merck.

'The Top Line' podcast: Why we need an Alzheimer's moonshot, a controversial take on diversity in biotech, plus this week's headlines

By Teresa Carey

This week on "The Top Line," we discuss why scientists say we need an Alzheimer's moonshot. We also talk about a controversial take on diversity during a panel at the BIO conference. Plus, we'll hear award-winning ads that tug at our heartstrings.

Article: Optimizing Oral Drug Delivery using Zydis®️ Orally Disintegrating Tablet Technology to Address Patient Challenges

Learn how innovation in the industry-leading Zydis ODT platform is expanding oral formulation options and bringing benefits to patients. Read now.